- Business Wire•11 hours agoFDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration has accepted the company’s Supplemental Biologics License Application for Actemra® for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition.
- Investor's Business Daily•4 days ago
Roche, Merck and Pfizer will likely disappoint on 2017 guidance, but AbbVie stock remains a "top pick" for Jefferies analyst Jeffrey Holford.
- PR Newswire•5 days agoBreakthrough development for Americans with suspected heart attack - Next generation Troponin T test from Roche cleared by FDA
OTCQX: RHHBY) announced that it has received the 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack. With this clearance, Roche is the first IVD company in the U.S. to provide the next generation Troponin testing for patients as an aid in the diagnosis of myocardial infarction, enabling clinicians to more accurately identify patients experiencing a heart attack. Every 43 seconds someone in the U. S. has a heart attack, or acute myocardial infarction (AMI), which occurs when the blood supply to an area of the heart is interrupted.
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||28.96 - 29.15|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.41|
|Dividend & Yield||1.02 (3.49%)|
|1y Target Est||N/A|